EGFR/HER2 inhibitor · small molecule
poziotinib
0 active trials across 3 of our biomarkers, targeting EGFR/HER2 exon 20. Not approved for any biomarker on marked.bio yet.
Also known as HM781-36B, NOV120101.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 0 | 7 | – |
| EGFR exon 20 insertion | 0 | 4 | – |
| HER2 (ERBB2) activating mutation | 0 | 6 | – |
Trials
0 of 10 trials shown
-
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
…n using a Food and Drug Administration (FDA)-approved in vitro diagnostic test (ie, cobas EGFR mutation test version \[v\] 2 or therascreen EGFR RGQ polymerase chain reaction \[PCR\] kit), a Cl…
EGFR exon 19 deletion / L858RMetastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
-
Study of Poziotinib in Japanese Patients With NSCLC
Phase 2: Documented EGFR or HER2 exon 20 insertion mutations (including duplication mutations) in NSCLC patients
HER2 (ERBB2) activating mutationNSCLC
-
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
poziotinibLoperamide
…E746\_A750del, A750P, S768I, S768I/V769L, S768I/V774M, L833V, V769M, V774M, R831C, R831H, L858R, L861Q, A864V.
EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationBreast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
-
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Cohort 1: Documented EGFR exon 20 insertion mutation (including duplication mutations)
EGFR exon 20 insertionHER2 (ERBB2) activating mutationNSCLC
-
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
…oundationOne Assay or by a Food and Drug Administration (FDA) approved device using cobas EGFR mutation test version (v)2 or therascreen EGFR RGQ PCt kit
EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationEGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
-
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Cohort 6: Participant with EGFR mutation-positive NSCLC who progressed while on treatment with first-line osimertinib
EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationNSCLC
-
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
Patients with HER2 mutation by sequencing
HER2 (ERBB2) activating mutationHER2 Gene Mutation, Adenocarcinoma Lung Stage IV
-
A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
HER2 mutation or EGFR mutation/gene amplification confirmed by CancerSCAN or Activated AR pathway confirmed by RNA seq \…
EGFR exon 19 deletion / L858RMetastatic Breast Cancer
-
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Documented EGFR mutation (e.g., exon 19 deletion, exon 21 L858R, etc.) with tumor tissue
EGFR exon 19 deletion / L858RAdenocarcinoma of Lung Stage IIIB, Adenocarcinoma of Lung Stage IV
-
NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Patients with EGFR mutation (e.g., G719X, exon 19 deletion, L858R, L861Q, etc) known to be associated with sensitivity to TKIs
EGFR exon 19 deletion / L858RIncreased Drug Resistance
No trials match these filters.